跳至主要内容
临床试验/NCT01594632
NCT01594632已完成不适用

A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II

FHI 3601 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
FHI 360
入组人数
650
试验地点
1
主要终点
Evaluate the contraceptive effectiveness of Sino-implant (II) during 4 years of use.

研究概览

简要总结

A study to assess the contraceptive effectiveness of Sino-implant (II).

详细描述

Randomized trial to assess the contraceptive effectiveness of Sino-implant (II) and to compare levonorgestrel concentrations, safety and acceptability of Sino-implant (II) and Jadelle.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 44 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • In good general health
  • Aged between 18 and 44 years, inclusive
  • Not pregnant
  • Not lactating
  • Not wishing to become pregnant in the next five years
  • Request long-acting reversible contraception
  • If previously used injectable contraceptives for pregnancy prevention, be more than 9 months since last injection of Depo-Provera and more than 3 months after the last injection of a combined injectable contraceptive
  • If previously used LNG-containing oral pills or implants, be more than 1 week after last hormone intake or implant removal
  • Be able to understand the information provided and to make personal decisions on participation
  • Consent to participation and sign a consent form
  • Agree and be able to return to the clinic for follow-up visits over five years

排除标准

  • acute deep venous thrombosis and/or pulmonary embolism or history of thromboembolic disease
  • systemic lupus erythematosus with positive or unknown antiphospholipid antibodies
  • unexplained vaginal bleeding
  • current or history of breast cancer
  • acute liver disease or cirrhosis
  • benign or malignant tumor of the liver
  • use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's Wort (Hypericum perforatum)
  • more than one sexual partner in the last 3 months
  • diagnosis or treatment for a sexually transmitted infection (STI) within the past 30 days for her or partner (excluding recurrent genital herpes or condyloma)
  • known HIV positive status for her or partner
  • any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation
  • BMI greater than or equal to 30 (for the sub-group of women with intensive LNG sampling)

研究组 & 干预措施

Jadelle

Experimental

Contraception using Jadelle implant

干预措施: Jadelle (Drug)

Sino-implant (II)

Active Comparator

levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]

干预措施: Sino-implant (II) (Drug)

结局指标

主要结局

Evaluate the contraceptive effectiveness of Sino-implant (II) during 4 years of use.

时间窗: 4 years

Pearl Index (number of pregnancies per 100 woman-years) over 4 years of use of Sino-implant (II).

次要结局

  • Evaluate the contraceptive effectiveness of Sino-implant (II) during 5 years of use(5 years)
  • Compare concentrations of levonorgestrel through 5 years after insertion of Sino-implant (II) and Jadelle(5 years)
  • Compare free levonorgestrel index through 5 years after insertion of Sino-implant (II) and Jadelle in a sub-group of approximately 150 users.(5 years)
  • Compare pharmacokinetic profiles of Sino-implant (II) and Jadelle during the first 6 months of use in a sub-group of users undergoing intensive levonorgestrel sampling(5 years)
  • Compare the safety and acceptability of Sino-implant (II) and Jadelle during 5 years of use(5 years)

研究者

发起方
FHI 360
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Safety,Effectiveness and Acceptability of... | 临床试验